Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation
Autore:
Simonsson, B; Totterman, T; Hokland, P; Lauria, F; Carella, AM; Fernandez, MN; Rozman, C; Ferrant, A; de Witte, T; Zander, AR; Meier, K; Hansson, F;
Indirizzi:
Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden Univ Uppsala Hosp Uppsala Sweden S-75185 pt Med, S-75185 Uppsala, Sweden
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 11, volume: 25, anno: 2000,
pagine: 1121 - 1127
SICI:
0268-3369(200006)25:11<1121:R(VPIA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; REACTIVE OXYGEN METABOLITES; KILLER CELL-ACTIVITY; COMPLETE REMISSION; NK CELL; T-CELL; IMMUNOMODULATOR LINOMIDE; MONONUCLEAR-CELLS; PERIPHERAL-BLOOD;
Keywords:
roquinimex; linomide; ABMT; AML;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Simonsson, B Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden Univ Uppsala Hosp Uppsala Sweden S-75185 85 Uppsala, Sweden
Citazione:
B. Simonsson et al., "Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation", BONE MAR TR, 25(11), 2000, pp. 1121-1127

Abstract

Roquinimex, Linomide, a quinoline derivative with pleiotropic immunomodulatory activity, has previously been shown to enhance natural killer (NK) cell number and activity after ABMT in patients with ARIL. In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. Out of 139 patients in each group, 109 Roquinimex patients and 108 placebo patients werein their first CR, Median age at inclusion was 41 years for Roquinimex patients and 39 years for placebo patients. Twelve patients in each group had their marrow purged prior to reinfusion, Relapse and death were study endpoints, Surviving patients were followed for 2.6 to 6.9 years, The total number of relapses was 60 in the Roquinimex group and 63 in the placebo group (not significant). Leukemia-free and overall survivals were similar in the two groups. Recovery of platelet counts was significantly delayed in the Roquinimex group as compared to placebo, No other significant differences regarding toxicity parameters were recorded. In conclusion, previous findings on NK cells could not be confirmed and the study showed no benefit for Roquinimex over placebo regarding relapse or survival following ABMT for AML in remission.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 13:13:19